CHICAGO, July 31 (Reuters) - Quest Diagnostics (DGX.N) on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein which can appear years before dementia symptoms arise.
The $399 test, called AD-Detect, uses the same technology as a blood test the company launched for use by doctors in early 2022.
Users must first pay for the test on Quest's website.
Quest will then arrange for an appointment with a telemedicine doctor to order it on their behalf.
Quest's lab-developed test, created and performed in a single laboratory, has not undergone any FDA review.
Persons:
Michael Racke, Biogen, Eli Lilly, Racke, Julie Steenhuysen, Richard Chang
Organizations:
Quest Diagnostics, Monday, U.S . Food, Drug Administration, Thomson
Locations:
Eisai, Alzheimer's